Curriculum vitae Johannes Kraemer

Name: Dr. Johannes Krämer
Date of birth: July 18, 1959 in Saarbrücken, Germany
Family status: married
Nationality: German
e-mail: jkraemer@phast.de

University

Pharmacy Course
Johann Wolfgang Goethe-University,
Frankfurt am Main/Germany

Registered Pharmacist for Germany

Specialization for Pharmaceutical Analysis (Fachapotheker)

Ph.D. in Pharmaceutical Technology and Biopharmaceutics,
Ruprechts-Karls-University, Heidelberg/Germany

Professional Experience

1988 – 1998	Head of Department Biopharmaceutics, Deutsches Arzneiprüfungsinstitut (German drug testing institute) and Head of Department Biopharmaceutics / Stability testing, Zentrallaboratorium Deutscher Apotheker; Eschborn/Germany
1998 – 2002	Founder and CEO, LQS GmbH, Eschborn/Germany
since January 2003	Founder and CEO, PHAST GmbH, Homburg/Germany www.phast.de
since April 2007	Founder and CEO of „flexible 4 science“ GmbH, Homburg/Germany, www.flexible4science.de

Boards

since 2004	Founder and director of scientific non-profit organization Biopher e.V., Homburg/Germany, www.biopher.de
2005-2010	Elected member of United States Pharmaceopeia Biopharmaceutics Expert Committee
2005-2010	Chair of United States Pharmacopeia Ad hoc Advisory Panel Performance Test Mucosal
since 2010	Elected member of United States Pharmaceopeia Dosage Form Expert Committee

Other Qualification

Qualified Person according to German law (§ 15, AMG)

Governmental investigator for drug testing (§ 65, AMG)

Membership

Member of United States Pharmacopeia Proficiency Testing Advisory Panel

Member of Executive Committee at FIP Section Laboratory Medicines Control

Member of FIP Special Interest Group In vitro Dissolution/Drug Release Performance Testing

Member of APV Focus Group Biopharmacy and Pharmacokinetics

Editorship

Dressman J.; Krämer J.(eds.): Pharmaceutical Dissolution Testing, Taylor & Francis (New York, 2005)

Research Interests

In vitro drug performance testing, drug release testing

Selected Publications

1. KRÄMER, J.; SIEWERT, M.; BLUME, H.; STRICKER, H.: Extended Release Theophylline, In vitro Modelling of Food Effects. In: *Archiv d. Pharmazie* 324 (1991), Nr. 9, S. 699
2. KRÄMER, J.; LINDAUER, R.F.; SIEWERT, M.; STRICKER, H.; BLUME, H.: Extended-Release Theophylline Alternative In Vitro Dissolution Methods. In: *Eur. J. Drug Metabolism. Pharmacokin.* 18 (1993), Nr. 1, S. 37
3. KRÄMER, J.; BLUME, H.: Biopharmaceutical Aspects of Multiparticulates. In: GHEBRE-SELASSIE, I. (ed.): Multiparticulate Oral Drug Delivery. New York: Marcel Dekker Inc., 1994, S. 307-332
4. KRÄMER, J.; REHM, K.-D.; BLUME, H.: Sotalol-Hydrochlorid Fertigarzneimittel. In: *Pharm. Ztg.* 139 (1994), Nr. 50, S. 4432-4438
5. BLUME, H.; ALI, S.L.; ELZE, M.; KRÄMER, J.; WENDT, G.; SCHOLZ, E.M.: Relative Bioverfügbarkeit von Paracetamol in Suppositorienzubereitungen im Vergleich zu Tabletten. In: *Arzneim. Forsch./Drug Res.* 44 (II), (1994) Nr. 12, S. 1333-1338
6. KRÄMER, J.; BLUME, H., STRICKER H., VOEGELE D.: Entwicklung der In-vitro-Freisetzungsmethode für ein Theophyllin-Retardarzneimittel auf der Basis von In-vitro-/ In-vivo-Korrelationen. In: Abstractband DPhG Jena (1995), S. DV 82
7. KRÄMER, J.; VOEGELE, D.; BLUME, H.: Einfluß von fettem Essen auf die Liberation und Resorption von Theophyllin im Magen-Darm-Trakt am Beispiel einer verlängert freisetzenden oralen

Zubereitung. In: Abstractband Colon Resorption und Colon Targeting, Universität Düsseldorf 29.11.96

8. KRÄMER, J.: Role of In Vitro Dissolution: Progress and Unresolved Issue. In: MIDHA, K.K, NAGAI, T. (eds.): Bioavailability, Bioequievalence and Pharmacokinetic Studies (FIP Bio-International ´96). Tokyo: Business Center for Academic Societies Japan (BCASJ), 1996, S. 303-311
9. KRÄMER, J.; ELZE, M.; FIEGER-BUESCHGES, H.; POTTHAST, H.; BLUME, H.: Level B Correlation to detect Biorelevant Manufacturing Changes of a propafenon Immediate Release Dosage Form by in vitro dissolution. In: *Pharm. Res.* 14 (1997), Nr. 11 (Supplement), S. S-121
10. LOEBENBERG, R.; SHAH, V.; KRÄMER, J.; DRESSMAN, J.C.: Dissolution Testing as a prognostic tool for oral drug absorption - dissolution behaviour of glibenclamide, a case II compound. In: *Pharm. Res.* 14 (1997), Nr. 11 (Supplement), S. S-523
11. KRÄMER J.: IVIVC – A Perspective from the Workbench. In DRESSMAN J.; LENNERNÄS H. (eds.): Oral Drug Absorption – Prediction and Assessment, *Marcel Dekker* (New York, 2000)
12. KRÄMER J.; GRADY L.T.; GAJENDRAN J.: Historical Development of Dissolution Testing. In: DRESSMAN J.; KRÄMER J.(EDS.): Pharmaceutical Dissolution Testing, *Taylor & Francis* (New York, 2005)
13. KRÄMER J.; STEINMETZ R.; STIPPLER E.: Dissolution Method Development With a View to Quality Control. In: DRESSMAN J.; KRÄMER J.(EDS.): Pharmaceutical Dissolution Testing, *Taylor & Francis* (New York, 2005)
14. VOGT M.; DERENDORF H.; KRÄMER J., et al.; Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisolone. In: *J. Pharm. Sci.*, Vol. 96, 1 (2007), 27
15. VOGT M.; DERENDORF H.; KRÄMER J. et al.; Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisone. In: *J. Pharm. Sci.*, Vol. 96, 6 (2007), 1480
16. GAJENDRAN J.; KRÄMER J.; KNUDSEN S.R.; Product Performance Test for medicated chewing gums. In: *Pharmacopeial Forum*, 34, 3 (2008), 843-847
17. BROWN C.K.;BUHSE L.; FRIEDEL H.-D.; KEITEL S.; KRÄMER J. et al. FIP Position Paper on Qualification of Paddle and Basket Dissolution Apparatus. In: *AAPS PharmSciTech.* (2009), DOI: 10.1208/s12249-009-9291-5